ABSTRACT Respiratory tract disease is surpassed only by mental health as the top-most costly and frequent medical condition affecting our children and resulting in adult disease with perinatal-pediatric origins. "The overall goal of LungMAP is to build a comprehensive molecular and cellular atlas of the human lung to serve as a reference platform to better understand both normal biology and disease pathobiology, and to identify critical cellular components, molecular pathways, and novel therapeutic targets in lung disease." Discovery of meaningful treatments for these disorders is limited by the rarity of access to sufficient normal and diseased human lung for high resolution, multi-scale study. Having, as the original Human Tissue Core (HTC) for the Molecular Atlas of Lung Development Program (LungMAP), created the BioRepository for INvestigation of Diseases of the Lung (BRINDL), encouraged and facilitated use of these biospecimens in highly productive collaborations between LungMAP HTC and RCs, developed new techniques for preserving and assaying these high-quality human tissues, and distributed biospecimens to the research community, the University of Rochester Medical Center (URMC) submits this renewal application in response to single source RFA-HL-24-015 to continue to serve as the HTC for LungMAP Phase 3. Begun as a repository for normal pediatric development, LungMAP II extended to include pediatric rare diseases including bronchopulmonary dysplasia, chILD, pulmonary hypoplasia and the more common disease, asthma. In Phase III, our proposal closely follows the Notice of Funding Opportunity that summarizes the "main goal of the HTC in Phase 3 is to catalog, store, and distribute human lung samples from the current LungMAP repository and from the LungMAP Research Centers (RCs)." The HTC will, while complying with current NIH and regulatory policies, selectively add pediatric rare lung diseases and certain healthy pediatric cases, enhance diversity in ethnicity and ancestry, assist Research Centers in acquiring diseases of their expertise, organize all case metadata within BRINDL, improve the BRINDL specimen and data management and distribution system (https://brindl.urmc.rochester.edu), integrate with the DCC portal system to improve user experience, and prepare to transition the biorepository at LungMAP sunset.